
usd jul pm et
summari compani make market comprehens line product servic treat
price-to-earnings oper ep
risk assess reflect compani highli
competit industri character technolog
innov new market entrant rang
start-up establish medic product develop
compani must consist enhanc product
develop new one maintain competit stand
howev demand product immun econom
cycl tend exhibit stabl long-term unit price
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
expect sale grow
billion follow rise
ew could rapidli expand margin cut
sg spend encourag
manag long-term focu
expect revenu growth slightli outpac
oper expens lead oper
margin compar
ew largest busi transcathet heart
valv therapi thvt busi
revenu expect grow
approxim roughli
billion sale continu adopt
expans transcathet aortic valv
increas competit
tavr market late caus ew lose
insignific amount market share
launch ultra centera
expect ew regain share
maintain lead market share
competit across cardiovascular product
intens longer-liv age world
popul aim address heart diseas
think thvt market particip benefit
expand market
think share trade
ep near fair valu share
appreci significantli far
recent product launch posit data
present march show
tavr provid superior non-inferior
outcom surgic altern ew
leader grow tavr space
continu innov view ew grow
 margin favor
commit like enabl ew establish
leadership nascent market
minimally-invas transcathet tricuspid
market tmtt grow compound-annual-growth-rate
least
risk recommend target
includ market share loss key product
categori difficulti commerci
product pipelin possibl
expect futur market structur heart
therapi smaller anticip
target reflect
multipl ep
estim high-end ew
rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp ew develop manufactur market product
technolog design treat advanc stage cardiovascular diseas ew categor
product technolog four main area transcathet aortic valv replac tavr formerli
transcathet heart valv therapi segment surgic structur heart formerli surgic heart valv
therapi critic transcathet mitral tricuspid therapi tmtt
ew leader transcathet heart valv replac technolog design nonsurg
replac heart valv edward sapien famili valv transcathet aortic heart valv
use treat patient heart valv diseas tradit open-heart surgeri
sub-optimal ew began offer transcathet heart valv patient commerci europ
unit state japan sale ew transcathet heart valv repres
net sale respect
surgic structur heart segment core product line carpentier-edward perimount
pericardi valv platform includ valv aortic mitral surgic valv replac ew
leader surgic structur heart therapi includ product annuloplasti ring
beating-heart mitral repair system ew acquir harpoon medic inc decemb sale
ew surgic tissu heart valv product repres net sale
respect
critic segment make hemodynam monitor system ew world leader
measur patient heart function fluid statu surgic intens care set hemodynam
monitor enabl clinician balanc suppli demand oxygen critic ill patient
play import role enhanc surgic recoveri enabl appropri tissu organ perfus
ultim enabl improv patient outcom surviv sale ew core
hemodynam product repres net sale
ew tmtt segment work develop commerci transcathet heart valv repair
replac technolog design treat mitral tricuspid valv diseas
technolog earli clinic phase ew cardioband system mitral tricuspid valv
reconstruct commerci avail europ expect therapeut area experi rapid
growth come year
competit landscap cardiovascular diseas number one caus death world
top diseas term health care spend nearli everi countri cardiovascular diseas progress
tend worsen time often affect structur individu heart result
compani aim treat cardiovascular diseas highli profit face sever competit
cardiovascular segment medic technolog industri dynam subject signific
chang due cost-of-car consider regulatori reform industri custom consolid well
evolv patient need
tavr segment ew primari competitor includ plc boston scientif corpor
surgic structur heart ew primari competitor includ plc
livanova plc critic ew compet primarili varieti compani specif product line
includ inc pulsion medic system se lidco group plc transcathet mitral
tricuspid therapi ew primari competitor although mani compani
develop effort field
key maintain grow market share medic devic industri upkeep product
research develop program ew invest substanti effort spend
million sale compar million sale million
favor view ew increas spend expect compani continu
invest heavili
financi trend revenu grew billion billion five-year
compound annual growth rate compound-annual-growth-rate revenu year end decemb adjust
ep vs reflect five-year compound-annual-growth-rate ew typic maintain
net cash posit gener posit free cash flow defin cash flow oper less
capit expenditur free cash flow million vs million compani
capit structur posit cash flow provid compani substanti flexibl
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
ew overvalu usd
bullish sinc june technic indic ew
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
driven growth global transcathet heart valv therapi
thvt busi surgic structur heart sale grew healthi aortic unit
volum adopt newer premium aortic valv critic sale
increas gross margin widen reflect better mix
fx continu favor view ew leadership posit structur
heart therapi market expect market rapidli expand upon
present data trial march expect
posit ew kevin huang cfa angelo zino cfa
pm et cfra lower opinion share buy
strong buy ew rais target
above-p ep estim continu
favor view ew leadership posit structur heart therapi market
expect market rapidli expand upon present data
trial march expect posit ew share
ew trade approxim morn news settlement
ew agre pay million settl
long-stand patent disput europ part
settlement compani agre litig disput relat
transcathet aortic valv certain mitral valv repair devic left
atrial appendag closur devic view posit
compani clear air enabl two medic devic
manufactur focu effort capit rapidli grow
analyst research note compani news
et cfra cut opinion share corp
hold buy ew lift target
base multipl ep high-end
ew five-year rang encourag sustain
ew long-term growth time see less upsid potenti
share high investor expect ep vs
surpass estim rais ep estim
underli sale growth acceler
preced quarter driven growth transcathet aortic valv
replac tavr sale believ present low risk data
march key driver tavr growth anticip fda approv
sapien sapien ultra low surgic risk patient ew made
strateg decis discontinu centera valv opt instead focu
effort sapien ultra also expect strong growth acceler
sale mitral repair devic /kevin huang cfa
et cfra reiter buy opinion share
corpor ew maintain target
above-p multipl ep estim
higher end ew five-year rang encourag
sustain ew long-term growth ep vs
estim lift ep estim
underli basi net sale rose driven growth global
transcathet aortic valv replac tavr busi expect
introduct ew sapien ultra ultra centera tavr
system europ insignific impact sale growth manag
note ultra system differ predecessor mean
benefici ew properli educ clinician use continu
expect outstand potenti ew new system especi
anticip long-term tavr tailwind studi result /kevin
et cfra reiter buy opinion share
corpor ew lift target base
multipl ep estim near high-end
ew five-year rang rais price target
forward earn multipl today posit data present
weekend ew sapien transcathet aortic valv replac tavr system
result studi show sapien superior
non-inferior surgic aortic valv replac savr tavr demonstr
lower rate all-caus death stroke rehospit primari
endpoint studi given result studi expect
market tavr expand rapidli origin anticip
especi patient low surgeri risk lift ep
estim higher growth expect /kevin huang cfa
pm et cfra add share health corpor top
portfolio ew think cvs-aet combin
tremend upsid potenti aet rapidli grow exposur
medicar advantag plan plan redesign in-stor experi
pharmaci custom merger also elimin risk lose aet
busi revenu enabl incentiv aet
million health plan particip use servic share
current trade ep estim appear discount us
replac ew top portfolio
et cfra keep buy opinion share
corpor ew rais target
above-p ep estim higher-end
ew five-year rang favor view ew exposur
nascent minimally-invas mitral tricuspid replac repair market
maintain ep estim introduc
ew post ep vs match consensu sale rose
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim ew earn
usd quarter fiscal year ew
announc earn per share usd repres
total revenu estim fiscal year
analyst estim ew earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
